Navigation Links
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Date:9/2/2008

a 14-day study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). The study is proceeding as planned. Top-line results from the triple combination study are anticipated to be released in the fourth quarter of 2008.

About Hepatitis C

The hepatitis C virus (HCV) is transmitted primarily through blood or blood products. HCV chronically affects 180 million people worldwide, which makes it over four times more prevalent than HIV. It is a leading cause of cirrhosis, liver cancer and liver failure, despite the fact that many patients can be cured.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... 2 HUYA Bioscience,International (HUYA), a rapidly ... key disease-fighting drugs sourced from China,announced today ... stage anti-arrhythmic,compound from the prestigious Shanghai Institute ... The compound, HBI-3000 or sulcardine, exhibits ...
... Cost-Effective, Time-Saving, ATLANTA, Oct. 1 ... CliniCom(TM), a revolutionary software platform,designed to assess ... CliniCom(TM), an intuitive, computer assisted intake ... health settings, gathers information,directly from patients and ...
... Center,has awarded a five-year, $120-million extension of its ... also known,as NSBRI, of Houston. Under the extension, ... biomedical research in support of a,long-term human presence ... cooperative agreement began April 1, 1997, with,a value ...
Cached Biology Technology:HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 2HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 3Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 2Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 3
(Date:4/24/2014)... bend light, acting as a lens. Now, by exploiting ... to create inexpensive high quality lenses that will cost ... so inexpensive, the lenses can be used in a ... the field, scientific research in the lab and optical ... "What I,m really excited about is that it opens ...
(Date:4/23/2014)... heating may contribute to early fetal death according to ... Institute of Children,s Hospital Los Angeles and Ulaanbaatar, Mongolia ... In a paper published today in the journal ... statistical correlations" between seasonal ambient air pollutants and pregnancy ... one of the highest levels of air pollution of ...
(Date:4/23/2014)... news release is available in French and ... , Montreal, 23 April 2014Today, the CEC released its ... Binational Collaborative Approach to Conservation, which identifies 29 priority ... border that includes 11 different protected areas in the ... unique, highly diverse arid and semi-arid habitats inhabited by ...
Breaking Biology News(10 mins):Bake your own droplet lens 2Bake your own droplet lens 3Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3
... Kofi Annan shared his hope with a gathering of ... of Commitment on HIV/AIDS would have heralded a response ... "significant but insufficient". , Citing achievements in the core ... of prevention programmes, and the availability of drug therapies, ...
... account for many cases of immune deficiency, in particular ... Common Variable Immunodeficiency (CVID), report researchers in the July ... a new diagnostic test for these conditions, which make ... because of a lack of good tests. , IgA ...
... voices they hear to the number of faces they ... finding indicates that numerical perception is truly an abstract ... sense, said the researchers. The experimental approach also will ... they have a verbal capacity, understand similar abstract numerical ...
Cached Biology News:Progress on HIV/AIDS significant but insufficient 2Progress on HIV/AIDS significant but insufficient 3Progress on HIV/AIDS significant but insufficient 4Gene for immune deficiency syndromes found 2Monkeys understand numbers across senses 2
Request Info...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
Biology Products: